{"nctId":"NCT01896544","briefTitle":"Cholecalciferol Supplementation for Sepsis in the ICU","startDateStruct":{"date":"2014-01"},"conditions":["Hypovitaminosis D"],"count":30,"armGroups":[{"label":"Cholecalciferol Dose II","type":"ACTIVE_COMPARATOR","interventionNames":["Dietary Supplement: Cholecalciferol"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Dietary Supplement: Placebo"]},{"label":"Cholecalciferol Dose I","type":"ACTIVE_COMPARATOR","interventionNames":["Dietary Supplement: Cholecalciferol"]}],"interventions":[{"name":"Cholecalciferol","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* English or Spanish speaking\n* Within 24 hours of a suspected diagnosis of sepsis\n* Meeting criteria for sepsis (defined as suspected or confirmed infection AND at least one diagnostic criteria in each of the following groupings):\n\n  1. Vital signs:\n\n     1. Temperature: \\>38.3 Celsius (C) or \\<36 Celsius (C)\n     2. Heart rat e: \\>90/min, or \\>2 standard deviation above normal\n     3. Tachypnea (\\>20 breaths per minute)\n     4. Altered mental status\n     5. Positive fluid balance (\\>20 mL/Kg over 24 hrs)\n     6. Glucose \\>140 mg/dL in the absence of diabetes mellitus\n  2. Inflammatory markers:\n\n     1. white blood cell (WBC): \\>12,000 or \\<4,000\n     2. Normal WBC count with \\>10% immature forms\n     3. c-reactive protein (CRP) \\>2 standard deviation above normal value\n     4. Pro- calcitonin \\>2 standard deviation above normal value\n  3. Hemodynamic\n\n     1. Systolic blood pressure (SBP) \\<90 millimeters mercury (mmHg), Mean Arterial Pressure (MAP) \\<70mmHg or SBP decrease \\>40mmHg\n     2. Vasopressor therapy to maintain MAP \\>65mmHg\n  4. Organ dysfunction\n\n     1. Arterial hypoxemia arterial oxygen partial pressure/fractional inspired oxygen (PaO2/FiO2) \\<300\n     2. Acute Oliguria (UoP \\<0.5 mL/Kg/hr for at least 2 hours)\n     3. Cr increase \\>0.5 mg/dL\n     4. Coagulopathy: internationals normalized ratio (INR) \\>1.5 or a-partial prothrombin time (aPTT) \\>60 sec\n     5. Thrombocytopenia: Platelet (PLT) \\<100 thousand (K)\n     6. Hyperbilirubinemia: Total Bilirubin (Tbili) \\>4 mg/dL\n  5. Tissue perfusion\n\n     1. Lactate \\>2 mmol/L\n     2. Decrease cap refill or mottling\n\nExclusion Criteria:\n\n* Pregnant females or immediate post-partum status\n* \"Comfort measures only\" status\n* Inability to provide informed consent or have a surrogate consent\n* History of renal stones within the past year\n* History of hypercalcemia within the past year\n* Baseline serum total calcium \\>10 mg/dL\n* Established diagnosis associated with increased risk of hypercalcemia (e.g. metastatic cancer, sarcoidosis, multiple myeloma, primary hyperparathyroidism)\n* History of severe anemia (Hematocrit \\<25%)\n* Medications that affect vitamin D metabolism (e.g. antiepileptics, tuberculosis medication\n* Already enrolled or planning to enroll in a research study that would conflict with full participation in the current study or confound the observation or interpretation of the study findings","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Vitamin D Status 5 Days Following Supplementation With Cholecalciferol","description":"Subjects will receive 200,000 IU or 400,000 IU cholecalciferol suspension (vs. placebo) within 24 hours from the onset of a suspected case of sepsis during their hospitalization. Vitamin D status at the onset of a suspected case of sepsis will be compared to vitamin D status between 5-9 days after supplementation with cholecalciferol or placebo. To assess vitamin D status, we will measure serum and urine: 1) 25-hydroxyvitamin D; 2) 1,25-dihydroxyvitamin D; 3) 24,25-dihydroxyvitamin D; 4) Fibroblast growth factor 23; 5) Vitamin D binding protein; 6) LL-37; 7) Parathyroid hormone; 8) Albumin; 9) Calcium; and 10) Phosphorus levels.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"22","spread":null},{"groupId":"OG002","value":"29","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Immunological Profile 5 Days Following Supplementation With Cholecalciferol","description":"Subjects will receive 200,000 IU or 400,000 IU cholecalciferol suspension (vs. placebo) within 24 hours from the onset of a suspected case of sepsis during their hospitalization. Immunological profile at the onset of a suspected case of sepsis will be compared to the immunological profile between 5-9 days after supplementation with cholecalciferol or placebo. To assess the immunological profile, we will measure serum LL-37.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"52","spread":null},{"groupId":"OG002","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"54","spread":null},{"groupId":"OG002","value":"67","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Infection-related Complications Within 90 Days From the Onset of a Suspected Case of Sepsis","description":"Subjects will receive 200,000 IU or 400,000 IU cholecalciferol suspension (vs. placebo) within 24 hours from the onset of a suspected case of sepsis during their hospitalization. The incidence of infection-related complications will be assessed between the onset of suspected sepsis and 80-100 days after supplementation with cholecalciferol or placebo. To assess the incidence of infection-related complications, we will measure rates of: 1) ICU length of stay; and 2) hospital length of stay","paramType":"MEAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"13","spread":null},{"groupId":"OG002","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Infection-related Complications Within 90 Days From the Onset of a Suspected Case of Sepsis","description":"Subjects will receive 200,000 IU or 400,000 IU cholecalciferol suspension (vs. placebo) within 24 hours from the onset of a suspected case of sepsis during their hospitalization. The incidence of infection-related complications will be assessed between the onset of suspected sepsis and 80-100 days after supplementation with cholecalciferol or placebo. To assess the incidence of infection-related complications, we will measure rates of:\n\n1\\) 30 day hospital readmission; and 2) 30 day mortality.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Immunological Profile 5 Days Following Supplementation With Cholecalciferol","description":"Subjects will receive 200,000 IU or 400,000 IU cholecalciferol suspension (vs. placebo) within 24 hours from the onset of a suspected case of sepsis during their hospitalization. Immunological profile at the onset of a suspected case of sepsis will be compared to the immunological profile between 5-9 days after supplementation with cholecalciferol or placebo. To assess the immunological profile, we will measure serum hsCRP.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"106","spread":null},{"groupId":"OG001","value":"208","spread":null},{"groupId":"OG002","value":"119","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"98","spread":null},{"groupId":"OG002","value":"31","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":10},"commonTop":[]}}}